James Investment Research Inc. Buys Shares of 12,820 Jazz Pharmaceuticals PLC (JAZZ)

James Investment Research Inc. bought a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the third quarter, HoldingsChannel reports. The institutional investor bought 12,820 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,155,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tiverton Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $198,000. Moloney Securities Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $204,000. FDx Advisors Inc. bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $244,000. Sawtooth Solutions LLC bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $270,000. Finally, Redmile Group LLC bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $274,000. Hedge funds and other institutional investors own 92.66% of the company’s stock.

NASDAQ:JAZZ opened at $158.82 on Thursday. Jazz Pharmaceuticals PLC has a fifty-two week low of $128.58 and a fifty-two week high of $184.00. The firm has a market cap of $9.40 billion, a P/E ratio of 16.61, a P/E/G ratio of 0.85 and a beta of 1.04. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.62 and a current ratio of 3.76.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.23 by $0.26. Jazz Pharmaceuticals had a return on equity of 25.47% and a net margin of 24.20%. The company had revenue of $500.48 million for the quarter, compared to analyst estimates of $469.85 million. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 11.71 EPS for the current year.

In other Jazz Pharmaceuticals news, SVP Paul Treacy sold 1,309 shares of the stock in a transaction on Friday, August 10th. The stock was sold at an average price of $176.61, for a total value of $231,182.49. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Matthew P. Young sold 700 shares of the stock in a transaction on Monday, October 15th. The stock was sold at an average price of $158.08, for a total value of $110,656.00. Following the completion of the sale, the chief financial officer now owns 32,768 shares in the company, valued at approximately $5,179,965.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,378 shares of company stock worth $5,751,888. Insiders own 3.90% of the company’s stock.

A number of research analysts have recently commented on JAZZ shares. BMO Capital Markets increased their target price on Jazz Pharmaceuticals from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Wednesday, August 8th. Mizuho reiterated a “neutral” rating and set a $173.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, October 15th. Wells Fargo & Co reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Sunday, July 8th. BidaskClub lowered Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 18th. Finally, Citigroup increased their price target on Jazz Pharmaceuticals from $162.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday, July 10th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $192.76.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: What strategies should day traders use to execute a trade?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply